PIPE Members

University of Winnipeg

The University of Winnipeg is located in the downtown area of Winnipeg. It is geographically close to the National Research Council’s Institute for Bio-diagnostics, the Health Sciences Centre, and the National Microbiology Laboratory of the Public Health Agency of Canada. The University of Winnipeg The Department of Physics has begun a period of strategic growth into the areas of health and radiation physics, including research collaborations with the University of Manitoba, the Institute for Bio-diagnostics, and the Health Sciences Centre. The department is expanding their undergraduate degree specializations to include Radiation and Health Physics, Radiation Therapy, and Medical Physics. The PIPE project will be part of this growth strategy.

Winnipeg Regional Health Authority

The WRHA is an organization of committed professionals who support the delivery of health services and work to protect the health and promote the well being of the people who benefit from these services.  The Winnipeg Health Region serves residents of the City of Winnipeg as well as the Rural Municipalities of East and West St. Paul, with a total population of just over 700,000 people. The WRHA also provides health care support to nearly half a million Manitobans who live beyond these boundaries as well as residents of Northwestern Ontario and Nunavut who require the services and expertise available within the Winnipeg Health Region.

More than 28,000 people work in the WRHA. With an annual operating budget of nearly $1.8 Billion, the WRHA operates or funds over 200 health service facilities and programs. WRHA provides about one half million diagnostic services a year of which nearly 20,000 involve the use of medical isotopes. The objective of the WRHA is to develop a reliable supply of radioisotopes protecting Manitoba patients. The WRHA has committed facilities and management and technical expertise to PIPE, and as a likely ‘first customer’ has committed to purchasing products from PIPE subject to quality and price considerations.

Health Sciences Centre and University of Manitoba (Medicine/ Radiology) (Diagnostic Imaging /Radiopharmacy)

The University of Manitoba, Department of Radiology, includes the disciplines of Diagnostic Radiology, Therapeutic Radiology and Medical Physics. The Department of Radiology at the University of Manitoba has Royal College approved training programs in Diagnostic Radiology, Nuclear Medicine and Radiation Oncology.  The Department of Radiopharmacy is one of four public-sector tertiary level clinical-teaching facilities in Canada. It is a centralized operation responsible for the procurement, preparation, quality control and quality assurance of radiopharmaceuticals for nuclear medicine sites in the Cities of Winnipeg and Brandon.

A key role for the HSC in the PIPE proposal is to show how accelerator-based Mo-99 can be used in a clinical setting; and to act as an advisor to PIPE on issues related to radioisotope supply, technetium generator design, facility financing, and regional coordination for product distribution. PIPE products have to be user-friendly to radiopharmacies and nuclear medicine departments. HSC will evaluate distribution and recycling options for our processing facility, as well as provide regulatory support.

Acsion Industries Incorporated

Acsion Industries is a leading edge development company, based in Pinawa, Manitoba, tasked with commercializing electron beam or E-beam technologies. Acsion, through our various divisions and subsidiaries, focuses on the emerging field characterized as the ‘science of safety’. AcsionAcsion serves public and private clients who require assistance in increasing the levels of safety in their operations. Their expertise is in linear accelerators, nuclear energy field, health and radiation safety, environmental protection projects and material science. The centre piece for our E-beam treatment research is our MB 10-4 industrial linear accelerator.

Acsion will apply its extensive experience in commercial accelerator operations in healthcare and other sectors to commercialize the production of Mo-99.  Acsion will use its knowledge in computer modeling and extensive resources in applied radiochemistry to molybdenum target development for optimization of Mo-99 yield.  Acsion’s expertise in operational radiation safety, licensing and regulatory compliance gained from operating their own e-beam facility will enable it to make the manufacture and shipment of Mo-99 routine, safe and commercially efficient.